Somali I, Meydan N, Tarhan M O, Oztop I, Alacacioglu A, Yilmaz U
Ataturk Research and Training Hospital, Department of Medical Oncology, Izmir, Turkey.
J BUON. 2009 Jul-Sep;14(3):429-33.
Gastric cancer is the 4th most commonly diagnosed cancer and the 2nd leading cause of cancer death worldwide. In this study assessed were the efficacy and toxicity of the combination of epirubicin, cisplatin and UFT in patients with metastatic gastric cancer (MGC).
In this retrospective study 27 patients with MGC were treated with epirubicin 50 mg/m(2) and cisplatin 60 mg/m(2) i.v. on day 1 and subsequently UFT 250 mg/m(2)/day orally in divided doses for 21 days, followed by a 7/day rest (EP/UFT).
Response and toxicity evaluation was possible for 25 patients. Three complete (12%) and 2 partial (8%) responses were observed. With a median follow-up 37 weeks (range 15-117), the median progression-free survival (PFS) and overall survival (OS) were 24 and 31 weeks, respectively. WHO grade 3 or 4 toxicity included neutropenia in 3 (12%) patients and nausea/vomiting in 1 (4%) patient. Neutropenic fever developed in only 1 (4%) patient.
EP-UFT with lower UFT doses and without leucovorin support is a safe and effective regimen as first -line treatment of MGC.
胃癌是全球第四大常见诊断癌症，也是第二大致癌死亡原因。本研究评估了表柔比星、顺铂和优福定联合应用于转移性胃癌（MGC）患者的疗效和毒性。
在这项回顾性研究中，27例MGC患者在第1天接受表柔比星50mg/m²和顺铂60mg/m²静脉注射，随后优福定250mg/m²/天口服，分剂量服用21天，然后休息7天（EP/UFT方案）。
25例患者可进行疗效和毒性评估。观察到3例完全缓解（12%）和2例部分缓解（8%）。中位随访37周（范围15 - 117周），中位无进展生存期（PFS）和总生存期（OS）分别为24周和31周。世界卫生组织3级或4级毒性包括3例（12%）患者出现中性粒细胞减少，1例（4%）患者出现恶心/呕吐。仅1例（4%）患者发生中性粒细胞减少性发热。
低剂量优福定且无亚叶酸支持的EP - UFT方案作为MGC的一线治疗是一种安全有效的方案。
